{"groups":[{"description":"Treatments and dosing regimens: Durvalumab 1500 mg IV q3w (neoadjuvant) 1500 mg IV q4w (adjuvant post-radical cystectomy) Day 1 and Day 8 (gemcitabine 1000 mg/m2 IV) of each 21-day cycle (neoadjuvant) Day 1 and Day 8 (cisplatin 35mg/m2 IV) or Day 1 (cisplatin 70 mg/m2 IV) each 21-day cycle (neoadjuvant) Dosing will be adjusted based on renal function","id":"FG000","title":"Durvalumab + Gemcitabine + Cisplatin"},{"description":"Treatments and dosing regimens: Day 1 and Day 8 (gemcitabine1000 mg/m2 IV) of each 21-day cycle (neoadjuvant) Day 1 and Day 8 (cisplatin 35mg/m2 IV) or Day 1 (cisplatin 70 mg/m2 IV) each 21-day cycle (neoadjuvant) Dosing will be adjusted based on renal function","id":"FG001","title":"Gemcitabine + Cisplatin"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"154"},{"groupId":"FG001","numSubjects":"197"}],"type":"Terminated the study"},{"reasons":[{"groupId":"FG000","numSubjects":"379"},{"groupId":"FG001","numSubjects":"333"}],"type":"Continuing study off treatment"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"533"},{"groupId":"FG001","numSubjects":"530"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"530"},{"groupId":"FG001","numSubjects":"526"}],"type":"Started Neoadjuvant Treatment"},{"achievements":[{"groupId":"FG000","numSubjects":"417"},{"groupId":"FG001","numSubjects":"389"}],"type":"Completed Neoadjuvant Treatment"},{"achievements":[{"groupId":"FG000","numSubjects":"469"},{"groupId":"FG001","numSubjects":"441"}],"type":"Completed Radical Cystectomy"},{"achievements":[{"groupId":"FG000","numSubjects":"383"},{"groupId":"FG001","numSubjects":"0"}],"type":"Started Adjuvant Treatment"},{"achievements":[{"groupId":"FG000","numSubjects":"288"},{"groupId":"FG001","numSubjects":"0"}],"type":"Completed Adjuvant Treatment"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"comment":"Completion status is reported by treatment phase","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"533"},{"groupId":"FG001","numSubjects":"530"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Patients randomized to treatments Arm 1 or Arm 2, will be treated according to their renal function. Recruitment for borderline renal function patients will be limited to up to 20% of the targeted global population. Recruitment for patients with T2N0 disease will be limited to approximately 40% of the targeted global population; once the 40% cap has been reached, only T2-4N1M0 and T3-4N0M0 patients will be allowed to be enrolled onto the study. Completion status is reported by treatment phase"}